The nuclear accumulation of EGFR represents an ideal target for therapeutic intervention as it appears to rarely occur outside the context of cancer, yet drives tumor progression, therapeutic resistance, and correlates with worse patient outcomes [69–71]. The gene discussed is EGFR; the disease is cancer.